key: cord-0317874-tccjx093
authors: Chandak, Payal; Huang, Kexin; Zitnik, Marinka
title: Building a Knowledge Graph to Enable Precision Medicine
date: 2022-05-09
journal: bioRxiv
DOI: 10.1101/2022.05.01.489928
sha: 5cc58bcfb9bf39d4114eab88fca36eb0ce36afd9
doc_id: 317874
cord_uid: tccjx093

Developing personalized diagnostic strategies and targeted treatments requires a deep understanding of disease biology and the ability to dissect the relationship between molecular and genetic factors and their phenotypic consequences. However, such knowledge is fragmented across publications, non-standardized research repositories, and evolving ontologies describing various scales of biological organization between genotypes and clinical phenotypes. Here, we present PrimeKG, a precision medicine-oriented knowledge graph that provides a holistic view of diseases. PrimeKG integrates 20 high-quality resources to describe 17,080 diseases with 4,050,249 relationships representing ten major biological scales, including disease-associated protein perturbations, biological processes and pathways, anatomical and phenotypic scales, and the entire range of approved and experimental drugs with their therapeutic action, considerably expanding previous efforts in disease-rooted knowledge graphs. In addition, PrimeKG supports artificial intelligence analyses of how drugs might target disease-associated molecular perturbations by containing an abundance of ‘indications’, ‘contradictions’, and ‘off-label use’ drug-disease edges lacking in other knowledge graphs. We accompany PrimeKG’s graph structure with text descriptions of clinical guide-lines to enable multimodal analyses.

Precision medicine takes a personalized approach to disease diagnosis and treatment that accounts for the variability in genetics, environment, and lifestyle across individuals 1 . To be precise, medicine must revolve around data and learn from both biomedical knowledge and health records 2 . Nevertheless, many barriers to linking and efficiently exploiting medical information across healthcare organizations and biological scales slow down the research and development of individualized care 2 . While many have acknowledged the difficulties in linking existing biomedical knowledge to patient-level health records [2] [3] [4] [5] , few realize that biomedical knowledge is itself fragmented. Biomedical knowledge about complex diseases comes from different organizational scales, including genomics, transcriptomics, proteomics, molecular functions, intra-and inter-cellular communications, phenotypes, therapeutics, and environmental exposures. For any given disease, information from various organizational scales is scattered across individual publications, non-standardized data repositories, evolving ontologies, and clinical guidelines. Developing networked relationships between these sources can support research in disease-rooted precision medicine.

A resource that comprehensively describes the relationships of diseases to biomedical entities would enable the large-scale, data-driven study of human disease. Understanding the connections between diseases, drugs, phenotypes, and other entities could open the doors for many types of research to leverage recent computational advances, including but not limited to the study of disease phenotyping [6] [7] [8] , disease etiology 9 , disease similarity 10 , disease diagnosis [11] [12] [13] , disease treatments 14 , drug-disease relationships [15] [16] [17] , mechanisms of drug action 18 and resistance 3 , drug repurposing [19] [20] [21] , drug discovery 22, 23 , adverse drug events 24, 25 , combination drug therapies 26 , and so forth. Many researchers have developed knowledge graphs for individual diseases that have helped advance computational precision medicine within their respective disease area [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Nevertheless, the costs and extended timelines of these individual efforts demonstrate a need for a systematic data resource that could unify existing biomedical knowledge to enable the investigation of diseases at scale. While many primary data resources contain information about diseases, consolidating them into a comprehensive, disease-rich, and functional knowledge graph presents three challenges.

Firstly, existing approaches to network analysis of diseases require expert review and curation of data in the knowledge graph 29, 30, 43 . While incredibly detailed, such efforts require substantial manual labor and expensive expert input, making them difficult to scale. Secondly, there lacks a con-sistent representation of diseases across biomedical datasets and clinical guidelines. Rather than have a standardized disease ontology, database developers select the ontology that best suits their function from a multitude of biorepositories [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . Because each set of disease vocabulary was tailored for some to serve a unique purpose, their disease encodings overlap unsystematically and are often in conflict. For instance, ICD codes 50 are optimized for medical billing whereas MedGen 53 , PhenoDB 51 , and Orphanet 48 focus on rare and genetic diseases. Moreover, expertly curated disease descriptions in medical knowledge repositories do not follow any naming conventions 48, 55 . The lack of standardized disease representations and the multimodal nature of the datasets makes it challenging to harmonize biomedical knowledge at scale. Thirdly, the definition of a 'unique' disease remains medically and scientifically ambiguous. For instance, while autism spectrum disorder is considered a medical diagnosis, the condition has many subtypes linked to clinically divergent manifestations 56, 57 . Clinically studied disease subtypes often do not correlate clearly with those defined in disease ontologies. Although only three subtypes of autism have be clinically identified 57 , the Unified Medical Language System (UMLS) 46 describes 192, the Monarch Disease Ontology (MONDO) 44 describes 37, and Orphanet 48 describes 6. The challenge in reconciling disease entities is only exacerbated by the variety of synonyms and abbreviations available for any particular disease 58 and the difficulty in linking structured disease entities to unstructured names in text 59 .

Meaningful disease entity resolution across multimodal, non-standardized datasets is critical for developing knowledge graphs that will be useful for downstream precision medicine tasks.

While drug repurposing remains the focus of knowledge graph development 33, 37, 39, 42, 60-62 , considerable effort has been devoted to building knowledge graphs from biomedical literature 28, 31, 40 and clinical records 29, 30, 34, 63 . For example, the SPOKE network is a seminal effort that linked many heterogeneous biomedical databases to build a disease-centric knowledge graph 38 . Although SPOKE is limited to about 200 diseases and lacks multimodal connections between textual clinical guidelines and tabular molecular data, it has enabled many precision medicine efforts, including Nelson et al. 35 Here, we present the Precision Medicine Knowledge Graph (PrimeKG), a knowledge graph providing a holistic and multimodal view of diseases. We integrate 20 high-quality resources, biorepositories, and ontologies to curate this knowledge graph. PrimeKG systematically captures information about 17,080 diseases with 4,050,249 relationships representing ten major biological scales, including disease-associated perturbations in the proteome, biological processes and pathways, anatomical and phenotypic scales, and the entire range of approved and experimental drugs together with their therapeutic action, considerably expanding previous efforts in disease-rooted knowledge graph creation. We demonstrate that disease nodes in our multi-relational knowledge graph are densely connected to every other node type, including phenotypes, exposures, and seven others. We tune PrimeKG specifically to support artificial intelligence analyses to better understand how drugs might target disease-associated molecular perturbations by including an abundance of 'indications', 'contradictions', and 'off-label use' drug-disease edges, which are usually missing or sparse in other knowledge graphs. We supplement PrimeKG's rich graph structure with textual descriptions of clinical guidelines for drug and disease nodes to enable multimodal analyses. Finally, we address the disease entity resolution challenge by improving the correspondence between diseases in PrimeKG and disease subtypes found in the clinic, making PrimeKG-based analyses medically meaningful.

The Precision Medicine Knowledge Graph (PrimeKG) is heterogeneous, with 10 types of nodes and 30 types of undirected edges. To develop PrimeKG, we retrieved and collated the 20 primary data resources (detailed in Data Records section) as visualized in Figure 2a , identified relations across these resources as shown in Figures 2b and 2c , harmonized them into a rich, heterogeneous network as illustrated in Figure 2c , and augmented the drug and disease nodes in this network with textual descriptions as depicted in Figure 2d .

To develop a comprehensive knowledge graph to study diseases, we considered 20 primary resources and a number of additional repositories of biological and clinical information. Figure 2a provides an overview of all 20 resources. We selected datasets that provided widespread coverage of biomedical entities, including proteins, genes, drugs, diseases, anatomy, biological processes, cellular components, molecular functions, exposures, disease phenotypes and drug side effects.

These were high-quality datasets, either expertly curated annotations such as DisGeNet and Mayo Clinic, widely-used standardized ontologies such as Mondo Disease Ontology, or direct readouts of experimental measurements such as Bgee and DrugBank. A complete list of primary resources along with their processing steps is listed in the Data Records section. All our data curation and processing approaches are transparent, fully reproducible, and can be continually adapted as individual data resources evolve and new data become available.

To harmonize these primary data resources into PrimeKG, we selected ontologies for each node type, harmonized datasets into a standardized format, and resolved overlap across ontologies.

Defining node types and selecting common ontologies. Our knowledge graph consists of 10 types of nodes. The node types 'drug', 'disease', 'anatomy' and 'pathway' are respectively encoded as terms in DrugBank, Mondo, UBERON, and Reactome. Genes and proteins are treated as a single node type, 'gene/protein', and identified by Entrez Gene IDs. The node types 'biological process', 'molecular function', and 'cellular component' are defined using Gene Ontology terms.

Disease phenotypes extracted from HPO and drug side effects extracted from SIDER are collapsed into a single node type, 'effect/phenotype', that is encoded using HPO IDs. Finally, 'exposure' nodes are defined using the ExposureStressorID field, which contains MeSH identifiers provided by the Comparative Toxicogenomics Database. This is illustrated in Figure 2a where each database is coloured by the node type it defines. Moving forward, we interchangeably refer to 'gene/protein' nodes as proteins and 'effect/phenotype' nodes as phenotypes.

Harmonizing external data resources. We mapped the aforementioned processed datasets to ensure that all nodes were defined in their respective common ontologies. Next, we identified sources of information across different primary resources for each node type to maximise the number of relationships in PrimeKG (see Figure 2b ). We then restructured the datasets to follow the following format. For each node in the knowledge graph, we provide 'node index' which is a unique index to identify the node in our KG; 'node id' which indicates the identifier of the node from it's ontology; 'node type' which indicates the node type as defined in our knowledge graph;

'node name' which indicates the name of the node as provided by the ontology; and 'node source' which indicates the ontology from which 'node id' and 'node name' fields were extracted. For each edge in the knowledge graph, we provide 'relation' which is the name of the edge type that connects the two nodes; 'x index' which links to the 'node index' field; and 'y index' which also links to 'node index'. Finally, we renamed columns for consistency, dropped rows with NaN values, dropped duplicated edges and removed self loop edges from each individual dataset.

Resolving overlap between phenotype and disease nodes. Since both the Mondo Disease Ontology and Human Phenotype Ontology were developed by the Monarch Initiative, there was considerable overlap between phenotype nodes and disease nodes across the various datasets. Overlapping nodes were defined as effect/phenotype nodes in HPO that (i) had the same ID number as disease nodes in Mondo and (ii) could be mapped from HPO to Mondo using cross-references found in the Mondo ontology. To avoid duplicate nodes, these overlapping phenotype nodes were converted to disease nodes by manipulating edges in various datasets as follows. Let us define the set of overlapping phenotype nodes as P . Phenotype-phenotype edges extracted from the HPO ontology were converted to phenotype-disease edges if one phenotype node was in P and to diseasedisease edges if both phenotype nodes were in P . These converted edges were then dropped from the original phenotype-phenotype resource. Protein-phenotype edges extracted from DisGeNet were converted to protein-disease relations if the phenotype node was in P and removed from the group of protein-phenotype edges. Finally, for disease-phenotype and drug-phenotype relations, we dropped any edges where the phenotype was in P . Adding these edges to drug-disease relations would only introduce unnecessary noise to the indication, contraindication, and off-label use edges.

To construct the network structure of PrimeKG, we merged the harmonized primary data resources into a graph and extracted it's largest connected component as shown in Figure 2c . We integrated the various processed, curated datasets and cleaned the graph by dropping NaN and duplicate edges, adding reverse edges, dropping duplicates again and removing self loops. This version of the knowledge graph is available on our Harvard Dataverse as 'kg raw.csv'. To ensure that our knowledge graph was well-connected and did not have any isolated pockets, we extracted its 

As shown in Figure 2d , we extracted both textual and numerical features for drug nodes in the knowledge graph from DrugBank and Drug Central. Features from DrugBank mapped directly to the knowledge graph since drugs were coded using DrugBank identifiers. Some features had unique attributes for each drug, such as 'state', 'indication' and 'mechanism of action', and others had numerous attributes for each drug, such as 'group' and 'ATC level'. The latter set of features were converted to single text descriptions by joining features using conjunctions such as ';' and 'and'. Features in Drug Central were mapped to DrugBank IDs using their CAS identifiers, from the vocabulary that was retrieved from DrugBank. Once all features were mapped, text processing involved removing all tokens that are references in DrugBank (for example "[L64839]") with the help of regular expressions. For the half-life feature, we nullified locations where the text mentioned that no data was available. Finally, we converted numerical features into textual descriptions in order to standardize the feature set.

As an example, let us explore the features available for Prednisolone. Prednisolone is a glu- 

As shown in Figure 2d , we extracted textual features for diseases nodes in the knowledge graph from the Mondo Disease Ontology, Orphanet, Mayo Clinic, and UMLS. Features from all these sources were mapped to the 'node id' field of disease nodes, that was defined using the Mondo Disease Ontology. Since disease nodes were grouped as described in Technical Validation section, many diseases defined in the Mondo Disease Ontology (i.e., many 'node id' values) were collapsed into a single node (i.e., unique 'node index' values). Since disease features are mapped to Mondo identifiers, or the 'node id' field, it is possible for a single disease node in the knowledge graph, defined by a unique 'node index', to have multiple feature values for a given feature. We provide the available features in their entirety since we did not have the medical authority to summarize them into single descriptors.

Disease definitions from the Mondo Disease Ontology were directly extracted from the ontology file and unique for each 'node id'. Disease descriptions extracted from UMLS were mapped from CUI terms to Mondo and as a result, numerous for each 'node id'. We removed tokens that were references and URLs from UMLS disease descriptions using regular expressions. From Orphanet, we extracted definitions, prevalence, epidemiology, clinical description, and management and treatment. We mapped the features from Orphanet IDs to Mondo, and as a result, there were multiple for each 'node id'. We used regular expressions to fix formatting errors in the prevalence and epidemiology features.

We extracted the following disease features from Mayo Clinic's website: symptoms, causes, risk factors, complications, and prevention. Since the Mayo Clinic web-scrapping did not provide a unique identifier in any ontology, we mapped disease names in Mayo Clinic to those in the Mondo Disease Ontology. To develop this mapping, we used a strategy for grouping disease names that is described in detail in the technical validation. Briefly, we conducted automated string matching followed by manual approval of disease name mappings based on their BERT embedding simi- 

We proceed with a detailed description of the 20 primary data resources used to build PrimeKG.

Bgee gene expression knowledge base in animals. Bgee 74 contains gene expression patterns across multiple animal species. We retrieved gene expression data for humans from ftp://ftp.bgee .org/current/download/calls/expr calls/Homo sapiens expr advanced.tsv.gz on 31 May 2021.

Processing involved keeping only gold quality calls and ensuring that the anatomical entities were coded using the UBERON ontology. To extract only highly expressed genes in the anatomical entity, we empirically filtered the data to keep data with expression rank less than 25,000. After processing, we had 1,786,311 anatomy-protein associations where gene expression was found to be present or absent. DisGeNET knowledgebase of gene-disease associations. DisGeNET 76 is a resource about the relationships between genes and human disease that has been curated by experts. We retrieved curated disease-gene associations (version 7.0) from https://www.disgenet.org/static/disgenet a p1/files/downloads/curated gene disease associations.tsv.gz on 31 May 2021. The raw data file, 'curated gene disease associations.tsv' was not processed further and contains 84,038 associations of genes with diseases, and phenotypes.

Disease Ontology. Disease Ontology 47 groups diseases in many meaningful clusters by using clinically relevant characteristics. For instance, diseases are grouped by anatomical entity. We retrieved the ontology from https://raw.githubusercontent.com/DiseaseOntology/HumanDisea seOntology/main/src/ontology/HumanDO.obo on 29 Jun 2021. The raw data 'HumanDO.obo' is mapped to disease nodes in our knowledge graph. Since the Mondo Disease Ontology is not grouped anatomically or by clinical speciality, this will allow users of PrimeKG to explore disease nodes in a medically meaningful format.

DrugBank. DrugBank 77 is a resource that contains pharmaceutical knowledge. We retrieved the complete database (version 5.1.8) from https://go.drugbank.com/releases/5-1-8/downloads /all-full-database on 31 May 2021. Processing involved using the beautiful soup package to extract synergistic drug interactions. The processed data contains 2,682,157 associations. We also extracted drug features from the raw data. For over 14,000 drugs, we construct 12 drug features, including group, state, description, mechanism of action, ATC code, pharmacodynamics, half life, protein binding, and pathway.

We also retrieved information about drug targets from https://go.drugbank.com/releases Four integrated resources of physical protein-protein interactions. Protein-protein interactions are composed of experimentally-verified interactions between proteins. The interactions we consider are diverse in nature and include signalling, regulatory, metabolic-pathway, kinasesubstrate and protein complex interactions, which are considered as unweighted and undirected.

We use the human PPI network compiled by Menche et al. 82 as the starting resource. This resource integrates several protein-protein interaction databases, including TRANSFAC for regulatory interactions 83 , MINT and IntAct for yeast to hybrid binary interactions 84, 85 , and CORUM for protein complex interactions 86 . Additionally, we retrieve protein-protein interaction information from from BioGRID 87 and STRING 88 databases. We also consider the human reference interactome (HuRI) generated by Luck et al. 89 , specifically, we use the HI-union, a combination of HuRI and several related efforts to systematically screen for protein-protein interactions. The processed data contains 642,150 edges. 

As part of the technical validation, we explore the structure and connectivity of PrimeKG.

PrimeKG contains 129,375 nodes and 8,100,498 edges. Figure 1a shows a schematic overview of the graph structure, containing 10 types of nodes and 30 types of edges. We provide a breakdown of the number of nodes by node type and the number of edges by edge type in Tables 1 and 2, respectively. Figure 1b formation. This extensive clinical information describing the entire range of drugs and diseases is a unique characteristic of PrimeKG that makes PrimeKG stand out among its peer knowledge graphs. Figure 1c provides an example of the supporting information that is available across these features.

A case study in autism to evaluate the relevance of PrimeKG to clinical presentation of autism For downstream inferences made using PrimeKG to be conducive to studying human disease, disease nodes in PrimeKG would need to be medically relevant. To this end, we next analyze if PrimeKG's representation of diseases strongly relates to their clinical presentation by carrying out a case study on autism spectrum disorder. We were motivated to investigate autism because it not only has incredible clinical heterogeneity [94] [95] [96] but this heterogeneity has also been studied to identify clinically meaningfully subtypes 56, 57 . We gauged the relevance of disease nodes related to autism in PrimeKG in two steps: first, by performing the entity resolution for autism concepts across all relevant primary data resources (see Methods), and second, by examining the relationship between these autism concepts and clinical subtypes of autism.

We start by exploring whether autism disease nodes in PrimeKG reconciled the variation in autism concepts across databases and ontologies. For example, as demonstrated in Figure 3a , MONDO disease ontology has 37 disease concepts related to autism, whereas the UMLS has 192 autism-associated concepts and Orphanet has 6 autism-associated concepts. Although it is not immediately clear how these concepts relate to each other, we cannot develop a coherent knowl-edge graph without establishing connections between these concepts. To this end, we overcome this challenge by defining all nodes using the MONDO disease ontology and mapping all other vocabularies to diseases in MONDO as outlined in Figure 3a .

Finally, before using MONDO disease concepts as disease nodes in PrimeKG, we need to assess whether autism disease concepts in MONDO correlate with clinical subtypes of autism.

Autism has been shown to manifest as three clinical subgroups characterized primarily by seizures, multisystem and gastrointestinal disorders, and psychiatric disorders 57 . However, it was unclear how the 37 autism disease concepts in MONDO (see Figure 3a ) relate to the three clinically defined subtypes. There were many disease concepts in autism, such as 'Autism, susceptibility to, 1', 'Autism, susceptibility to, 2', 'Autism, susceptibility to, x-linked', etc., with no apparent clinical meaning, suggesting that disease nodes in MONDO do not correspond one-to-one to clinical manifestation of autism. For this reason, we developed a strategy to group diseases from MONDO into medically relevant and coherent nodes in PrimeKG. We proceed with describing and evaluating that strategy.

As demonstrated in our case study of autism, disease concepts in MONDO may not correlate well with medical subtypes. MONDO contains many repetitive disease entities with no apparent clinical correlation. For this reason, we were motivated to group diseases in MONDO into medically relevant entities. Ideally, we would have preferred to leverage expertise across a wide variety of disease areas when grouping these concepts. However, this approach was time-consuming, expensive, and challenging to execute at scale. Further, disease sub-phenotyping is a relatively new paradigm, and so we anticipated low consensus among medical experts on what constitutes a unique disease.

Since manually grouping diseases with expert supervision was not feasible, we took a semiautomated unsupervised approach to group disease concepts in PrimeKG. Advances in natural language processing, specifically the Bidirectional Encoder Representations from Transformers (BERT) model 97 , allowed us to study similarity between disease concept names. We grouped disease concepts with nearly identical names into a single node with string matching and BERT embedding similarity [97] [98] [99] [100] [101] .

We identified disease groups using a string matching strategy across disease names 102 . In this strategy, we selected a disease that ended with a number, or a roman numeral, or any alphanumeric phrase with a length of less than 2, or 'type' as the second-last word. Once such a disease was selected, we extracted the primary disease phrase by dropping the ending and used this phrase to find matches. Matches included diseases with the same initial phrase and those containing all phrase words with no other words regardless of word order. For the latter matching criteria, the words 'type' and '(disease)' were ignored. In this manner, we grouped disease concepts in MONDO with string matching.

We further tightened groupings identified using string matching by exploring word embedding similarities between disease names, which is visualized in Figure 3b . In natural language processing, word embeddings have been widely and successfully used to resolve conflicting and redundant entities in an unsupervised manner [102] [103] [104] , and deep language models such as BERT 97 can produce semantically meaningful word embeddings. Specifically, ClinicalBERT 105 is a BERT language model that encodes medical notions of semantics because it has been pre-trained on biomedical knowledge from PubMed 106 and discharge summaries from MIMIC-III 107 . We used ClinicalBERT to extract word embeddings for disease group names identified during string matching. We also defined similarity between two disease names as the cosine distance between their ClinicalBERT embeddings. Then, after applying an empirically chosen cutoff of similarity ≥ 0.98, we manually approved the suggested disease matches and assigned names to the new groups. Finally, these groupings were applied to the knowledge graph.

After this process, 22,205 disease concepts in MONDO were collapsed into 17,080 grouped diseases, which has resulted in a higher average edge density across diseases and more clinically relevant disease nodes. We anticipate that PrimeKG is a powerful dataset with this grouping because disease representations are concentrated and robust, which, in turn, can enable biological insights gleaned from PrimeKG to be medically relevant.

The potential uses of PrimeKG are vast. PrimeKG describes drug features on a deeper biological level and disease features on a deeper clinical level, which can be used to explain genotypephenotype associations in terms of genes, pathways, or any other nodes in an extensive knowledge graph, like PrimeKG. Consequently, PrimeKG can be paired with deep graph neural networks 108 to discover new disease biomarkers, characterize disease processes, hone disease classification, identify phenotypic traits, predict biological mechanisms, and repurpose drugs. With the implementation of machine learning functionality, we anticipate that PrimeKG and similar knowledge graphs will become critical tools in advancing precision medicine. Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. The half-life is 3 hours in extensive metabolizers. Though its precise mechanism of action is not fully understood, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain.

[...] Risperidone and its active metabolite, 9-hydroxyrisperidone, are ~88% and ~77% protein-bound in human plasma, respectively. [...] The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders.

Risperidone Figure 1 : Overview of PrimeKG. a) Shown is a schematic overview of the various types of nodes in PrimeKG and the relationships they have with other nodes in the graph. b) All disease nodes in PrimeKG shown in a circular layout together with disease-associated information. All relationships between disease nodes and any other node type are depicted here. Disease nodes are densely connected to four other node types in PrimeKG through seven types of relations. c) Shown is an example of paths in PrimeKG between the disease node 'Autism' and the drug node 'Risperidone'. Intermediate nodes are colored by their node type from panel a. We also display snippets of text features for both nodes to demonstrate the multimodality of PrimeKG. Abbreviations -MF: molecular function, BP: biological process, CC: cellular component, APZ: Apiprazole, EPI: epilepsy, ABP: abdominal pain, + / -associations: positive and negative associations. a) The left side shows three clinically determined subtypes of autism. The right side shows autism-related disease terms across three ontologies: MONDO, UMLS, and Orphanet. While we can identify mappings across the ontologies, it is unclear how the terms in any ontology connect to clinical subtypes. b) Illustration on how we use a language model, ClinicalBERT, to map terms from MONDO into a latent embedding space. Because the language model can group synonyms in the embedding space, we can cluster MONDO terms with similar semantic and medical meaning by calculating cosine similarity between embeddings of disease concepts. These clusters are created to develop disease groupings as shown on the right in panel b. Abbreviations -MONDO: MONDO disease ontology, UMLS: unified medical language system. Table 4 : Statistics on disease features in the knowledge graph. Unprocessed KG refers to the initial knowledge graph assembled from datasets. Processed KG refers to the fully processed PrimeKG, and includes disease groupings. The count column refers to the number of features including duplicates and the unique column refers to the number of unique features.

Precision medicine: opportunities, possibilities, and challenges for patients and providers

Big data hurdles in precision medicine and precision public health

Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer

From Big Data to Precision Medicine

Individualized knowledge graph: a viable informatics path to precision medicine

Computational Approaches to Phenotyping: High-Throughput Phenomics

Deep Learning Solutions to Computational Phenotyping in Health Care

Deep Computational Phenotyping

Protein interactions and disease: computational approaches to uncover the etiology of diseases

Computational Methods for Identifying Similar Diseases

Computational intelligence technique for early diagnosis of heart disease

Computational intelligence for heart disease diagnosis: A medical knowledge driven approach

Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome

Multi-scale Computational Models of Proangiogenic Treatments in Peripheral Arterial Disease

DR2DI: a powerful computational tool for predicting novel drug-disease associations

DrugNet: Networkbased drug-disease prioritization by integrating heterogeneous data

NEDD: a network embedding based method for predicting drug-disease associations

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action

Computational drug repositioning through heterogeneous network clustering

Exploiting drug-disease relationships for computational drug repositioning

Large-scale extraction of accurate drug-disease treatment pairs from biomedical literature for drug repurposing

A Survey on the Computational Approaches to Identify Drug Targets in the Postgenomic Era

Data-Driven Prediction of Drug Effects and Interactions

Using Machine Learning to Identify Adverse Drug Effects Posing Increased Risk to Women

A Computational Approach for Identifying Synergistic Drug Combinations

Developing a Search Engine for Precision Medicine

Building a PubMed knowledge graph

Knowledge Graph-Enabled Cancer Data Analytics

Construction of a knowledge graph for diabetes complications from expertreviewed clinical evidences

KGen: a knowledge graph generator from biomedical scientific literature

PharmKG: a dedicated knowledge graph benchmark for bomedical data mining

Knowledge-driven drug repurposing using a comprehensive drug knowledge graph

An integrative knowledge graph for rare diseases, derived from the Genetic and Rare Diseases Information Center (GARD)

Integrating biomedical research and electronic health records to create knowledge-based biologically meaningful machine-readable embeddings

Therapeutics Data Commons: Machine learning datasets and tasks for drug discovery and development

Artificial intelligence in COVID-19 drug repurposing

Systematic integration of biomedical knowledge prioritizes drugs for repurposing

Network medicine framework for identifying drug-repurposing opportunities for COVID-19

A global network of biomedical relationships derived from text

Scientific Language Models for Biomedical Knowledge Base Completion: An Empirical Study

Open Graph Benchmark: Datasets for machine learning on graphs

KGHC: a knowledge graph for hepatocellular carcinoma

The Monarch Initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species

The Human Phenotype Ontology in 2017

The Unified Medical Language System (UMLS): integrating biomedical terminology

Human Disease Ontology 2018 update: classification, content and workflow expansion

Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders

International statistical classification of diseases and related health problems (World Health Organization

PhenoDB: An Integrated Client/Server Database for Linkage and Population Genetics

MedDRA (medical dictionary for regulatory activities)

NCBI's Portal to Information on Medical Conditions with a Genetic Component

ORDO: an ontology connecting rare disease, epidemiology and genetic data

A multidimensional precision medicine approach identifies an autism subtype characterized by dyslipidemia

Comorbidity Clusters in Autism Spectrum Disorders: An Electronic Health Record Time-Series Analysis

MEDIC: a practical disease vocabulary used at the Comparative Toxicogenomics Database

Linking entities through an ontology using word embeddings and syntactic re-ranking

DRKH-drug repurposing knowledge graph for COVID-19

Drug Repurposing for COVID-19 via Knowledge Graph Completion

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Clinical knowledge extraction via sparse embedding regression (KESER) with multi-center large scale electronic health record data

CORD-19: The COVID-19 Open Research Dataset

AWS CORD-19 Search: A Neural Search Engine for COVID-19 Literature

Neural Ranking Models and Keyword Search Infrastructure for the COVID-19 Open Research Dataset

Network bioinformatics analysis provides insight into drug repurposing for COVID-19

Drug target discovery using knowledge graph embeddings

Discovering Protein Drug Targets Using Knowledge Graph Embeddings

A Literature-Based Knowledge Graph Embedding Method for Identifying Drug Repurposing Opportunities in Rare Diseases

Neural networks for link prediction in realistic biomedical graphs: a multi-dimensional evaluation of graph embedding-based approaches

Pre-training graph neural networks for link prediction in biomedical networks

OpenBioLink: a benchmarking framework for large-scale biomedical link prediction

The Bgee suite: integrated curated expression atlas and comparative transcriptomics in animals

Comparative Toxicogenomics Database (CTD): update 2021

The DisGeNET knowledge platform for disease genomics: 2019 update

DrugBank 5.0: a major update to the DrugBank database for

DrugCentral 2021 supports drug discovery and repositioning

Entrez Gene: gene-centered information at NCBI

GOATOOLS: A Python library for

The Gene Ontology Consortium et al. The Gene Ontology resource: enriching a GOld mine

Uncovering disease-disease relationships through the incomplete interactome

TRANSFAC ® : transcriptional regulation, from patterns to profiles

MINT, the molecular interaction database: 2009 update

The IntAct molecular interaction database in 2010

Corum: the comprehensive resource of mammalian protein complexes-2019

The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions

The string database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets

A reference map of the human binary protein interactome

The Reactome pathway knowledgebase

The SIDER database of drugs and side effects

Uberon, an integrative multi-species anatomy ontology

Challenges in clinical natural language processing for automated disorder normalization

Importance of studying heterogeneity in autism

Disentangling the heterogeneity of autism spectrum disorder through genetic findings

Heterogeneity within Autism Spectrum Disorders: What have We Learned from Neuroimaging Studies?

Pre-training of Deep Bidirectional Transformers for Language Understanding

Commonsense Transformers for Automatic Knowledge Graph Construction

Deep Communicating Agents for Abstractive Summarization

Knowledge Base Completion with Structural and Semantic Context

Discourse-Aware Neural Rewards for Coherent Text Generation

Lexicon Infused Phrase Embeddings for Named Entity Resolution

An Entity Resolution Approach Based on Word Embeddings and Knowledge Bases for Microblog Texts

DeepER -Deep Entity Resolution

Publicly available clinical BERT embeddings

BioBERT: a pre-trained biomedical language representation model for biomedical text mining

MIMIC-III, a freely accessible critical care database

Representation learning for networks in biology and medicine: Advancements, challenges, and opportunities